Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by
circulating autoantibodies that recognize cell surface phospholipids and phospholipid …

The prognosis in systemic lupus erythematosus (SLE) has improved due to better treatment
and care, but cardiovascular disease (CVD) still remains an important clinical problem, since …

Systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and Sjögren's
syndrome (SS) are heterogeneous autoimmune diseases. Severe manifestations and …

The objective of this work was to conduct a systematic literature review (SLR) and meta-
analysis (MA) to evaluate the relative risk (RR) of venous thromboembolism (VTE) events …

Objective Pathogenesis of antiphospholipid syndrome (APS) isn't fully elucidated. We aimed
to identify gene signatures characterizing thrombotic primary APS (thrPAPS) and subgroups …

Background Cardiovascular disease (CVD) is the foremost cause of morbidity and deaths in
antiphospholipid syndrome (APS), driven by thrombo-inflammation and atherothrombosis …

Hyperhomocysteinemia (HHcy) is a risk factor for chronic kidney diseases (CKDs) that
affects about 85% CKD patients. HHcy stimulates B cells to secrete pathological antibodies …

The antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized,
according to the Sydney criteria, by the persistent presence of autoantibodies directed …

Importance The prevalence of antiphospholipid antibodies (aPL) and their association with
future atherosclerotic cardiovascular disease (ASCVD) risk has yet to be thoroughly …

Background The optimal strategy for diagnosis and antithrombotic treatment of patients with
antiphospholipid syndrome (APS)–associated acute ischemic stroke (AIS), transient …